PMID- 36118549
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220920
IS  - 1927-1220 (Electronic)
IS  - 1927-1212 (Print)
IS  - 1927-1212 (Linking)
VI  - 11
IP  - 4
DP  - 2022 Aug
TI  - Treatment of Light Chain Deposition Disease: A Systematic Review.
PG  - 123-130
LID - 10.14740/jh1038 [doi]
AB  - Light chain deposition disease (LCDD) is a rare hematologic disorder that can 
      affect any organ but predominantly involves the kidneys. Existing literature is 
      limited to case reports and small single-center retrospective series, explaining 
      the lack of any treatment algorithms and management guidelines for patients with 
      this disorder. In this systematic review of literature, we explored the role of 
      standard and high-dose chemotherapy-autologous stem cell transplant for LCDD. A 
      total of 11 studies were identified to evaluate the hematologic and renal 
      responses to various treatment regimens. Autologous stem cell transplant and 
      bortezomib-based regimens appear to have reasonable safety and efficacy for this 
      rare hematologic disorder, albeit some statistical and analytical limitations. 
      Large multicenter retrospective and prospective studies are needed to better 
      elucidate the role of various chemotherapy regimens as well as autologous stem 
      cell transplant for patients with LCDD.
CI  - Copyright 2022, Masood et al.
FAU - Masood, Adeel
AU  - Masood A
AUID- ORCID: 0000-0001-7085-777X
AD  - Hematology/Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Ehsan, Hamid
AU  - Ehsan H
AD  - Hematology/Oncology, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
FAU - Iqbal, Qamar
AU  - Iqbal Q
AD  - Internal Medicine, Tidal Health Peninsula Regional, Salisbury, MD 21801, USA.
FAU - Salman, Ahmed
AU  - Salman A
AD  - Hematology/Oncology, Rochester Regional Health/Lipson Cancer Center, USA.
FAU - Hashmi, Hamza
AU  - Hashmi H
AD  - Hematology/Oncology, Medical University of South Carolina, Charleston, SC 29425.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220830
PL  - Canada
TA  - J Hematol
JT  - Journal of hematology
JID - 101635099
PMC - PMC9451548
OTO - NOTNLM
OT  - Autologous stem cell transplant
OT  - Bortezomib
OT  - Lenalidomide
OT  - Light chain deposition disease
OT  - Thalidomide
COIS- Authors do not have any conflict of interest to report.
EDAT- 2022/09/20 06:00
MHDA- 2022/09/20 06:01
PMCR- 2022/08/30
CRDT- 2022/09/19 04:13
PHST- 2022/07/23 00:00 [received]
PHST- 2022/08/13 00:00 [accepted]
PHST- 2022/09/19 04:13 [entrez]
PHST- 2022/09/20 06:00 [pubmed]
PHST- 2022/09/20 06:01 [medline]
PHST- 2022/08/30 00:00 [pmc-release]
AID - 10.14740/jh1038 [doi]
PST - ppublish
SO  - J Hematol. 2022 Aug;11(4):123-130. doi: 10.14740/jh1038. Epub 2022 Aug 30.